Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - alectinib hydrochloride, quantity: 161.33 mg (equivalent: alectinib, qty 150 mg) - capsule, hard - excipient ingredients: magnesium stearate; potassium chloride; carmellose calcium; maize starch; carnauba wax; hypromellose; hyprolose; titanium dioxide; lactose monohydrate; sodium lauryl sulfate; carrageenan; iron oxide red; iron oxide yellow; indigo carmine aluminium lake; shellac; glyceryl monooleate - alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive, locally advanced or metastatic non-small cell lung cancer (nsclc).

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - alectinib as hydrochloride - capsules - alectinib as hydrochloride 150 mg - alectinib is indicated for the treatment of patients with alk positive, locally advanced or metastatic non-small cell lung cancer (nsclc) who progressed on or are intolerant to crizotinibalecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc).

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoma, non-small-cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor.lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

European Union - English - EMA (European Medicines Agency)

roche registration gmbh - alectinib hydrochloride - carcinoma, non-small-cell lung - antineoplastic agents - alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc).alecensa as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc previously treated with crizotinib.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.